CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionSignaturefd, Llc
Latest Disclosed Ownership1,544 shares
Latest Disclosed Value $ 73,448
Signaturefd, Llc reports 2.80% increase in ownership of CRSP / CRISPR Therapeutics AG

On April 7, 2026 - Signaturefd, Llc filed a 13F-HR form disclosing ownership of 1,544 shares of CRISPR Therapeutics AG (US:CRSP) valued at $73,448 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 20, 2026 disclosing 1,502 shares of CRISPR Therapeutics AG. This represents a change in shares of 2.80% during the quarter. The current value of the position is $80,041 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-07 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,544 42 2.80 73 -6.41 0.0011
2026-01-20 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,502 -70 -4.45 79 -22.77 0.0012
2025-10-21 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,572 -64 -3.91 102 27.85 0.0016
2025-07-16 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,636 -39 -2.33 80 38.60 0.0014
2025-05-02 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,675 -82 -4.67 57 -17.39 0.0011
2025-02-10 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,757 -160 -8.35 69 -23.33 0.0013
2024-10-21 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,917 -28 -1.44 90 -14.29 0.0017
2024-07-29 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,945 -15 -0.77 105 -21.05 0.0021
2024-05-03 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,960 58 3.05 134 11.76 0.0028
2024-02-01 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,902 -222 -10.45 119 23.96 0.0027
2023-11-03 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,124 236 12.50 96 -8.57 0.0025
2023-08-01 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,888 -17 -0.89 106 22.09 0.0027
2023-04-28 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,905 244 14.69 86 28.36 0.0024
2023-01-30 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,661 -364 -17.98 68 -49.24 0.0020
2022-11-08 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,025 253 14.28 132 22.22 0.0045
2022-08-10 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,772 -37 -2.05 108 -5.26 0.0037
2022-05-02 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,809 1,069 144.46 114 103.57 0.0034
2022-01-25 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 740 -195 -20.86 56 -46.67 0.0017
2021-10-28 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 935 -1,435 -60.55 105 -72.66 0.0036
2021-07-26 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,370 -90 -3.66 384 28.00 0.0153
2021-04-30 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,460 1,545 168.85 300 114.29 0.0133
2021-02-11 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 915 115 14.38 140 108.96 0.0066
2020-11-03 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 800 -65 -7.51 67 4.69 0.0036
2020-07-30 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 865 -75 -7.98 64 60.00 0.0039
2020-04-23 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 940 275 41.35 40 -2.44 0.0035
2020-02-05 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 665 0 0.00 41 51.85 0.0030
2019-10-16 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 665 0 0.00 27 -12.90 0.0022
2019-07-31 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 665 -20 -2.92 31 29.17 0.0027
2019-05-09 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 685 85 14.17 24 41.18 0.0020
2019-02-13 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 600 -1,700 -73.91 17 -83.33 0.0016
2018-11-14 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,300 -50 -2.13 102 -26.09 0.0104
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,350 1,300 123.81 138 187.50 0.0154
2018-05-08 2018-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,050 1,050 48 0.0056
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.